The Advantages of Restricted-Access Barrier Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Advantages of Restricted-Access Barrier Systems
Filling machines often are installed in sterile rooms and separated by isolators to prevent contamination. These methods have certain drawbacks, including making interventions more difficult. Restricted-access barrier systems are an alternative that ensures sterility and facilitates interventions.


Pharmaceutical Technology


Another important aspect of isolator technology is that it requires the biodecontamination of all machinery and isolator surfaces in the aseptic-process area before each production run. Biodecontamination is necessary because the isolator typically is opened for maintenance, format changes, cleaning, and product changeover. Opening the isolator removes the physical separation of the cleanroom and the potentially contaminated surrounding area. The most common biodecontamination systems for isolators use H2O2 vapor. In the conditioning phase, H2O2 vapor is introduced into the sealed isolator until it reaches a specified concentration. Next, H2O2 is held at this concentration for a specific duration. Finally, during the aeration phase, the H2O2 vapor is removed by purging the isolator with fresh, filtered air. This process can take 3–10 h, depending on the biodecontamination system, isolator size, surface areas, and air-filter size. During this period, the process line cannot be used, although other procedures such as cleaning and steaming in place of the filling system can be performed during aeration.


Table I: A comparison of cleanrooms, restricted-access barrier systems (RABS), and isolators.
The long duration of a biodecontamination cycle reduces operational flexibility when working with an isolator. This procedure, however, does guarantee that each production run begins with a biodecontaminated system, which is nearly sterile (demonstrating a 6-log inactivation of biodecontaminants).

Manual operations within the aseptic area are more difficult with isolators. Gloveports must be used in place of direct operator access. This technique requires greater reliability and automation for process machinery inside an isolator than is required in a traditional cleanroom. All interfaces, gloveports, mouseholes, and transfer ports must be integrated into the physical barrier because they separate the clean process area from the potentially contaminated exterior areas.

Isolators always have their own air-handling system to maintain production conditions and achieve the optimal conditions for the biodecontamination cycle.

RABS: an alternative. The restricted-access barrier system (RABS) can be an alternative to isolators and cleanrooms. The RABS concept entails a physical barrier between operators and production areas, but the barrier is limited. A limited barrier is acceptable because RABS always must be set up in high-class cleanrooms (at least ISO 7). Thus, RABS do not require their own biodecontamination system (6).

Guidelines and standards for RABS


Figure 3: Vial-filling line with a passive RABS.
To date, no specific standards or regulations for RABS have been developed. Manufacturers should follow existing norms and regulations for the basic processing of sterile pharmaceutical products. Operators can consult ISO Standard 14644, Part 7 for guidance when using RABS as a protective solution (5). Appendix A of Part 7 features a diagram that shows the reliability of a separation versus the separation method. It demonstrates that RABS can be considered an aerodynamic measure that has a high physical separation. The system's interior atmosphere can be controlled, but pressure control is limited. In contrast, the diagram shows that isolator solutions have a small leak rate and appropriate positive or negative pressure control.

The US Food and Drug Administration is the first authority to offer preliminary definitions of the approximately 75 existing RABS installations worldwide (6). A working group of industrial experts drafted a definition of RABS and guidelines for RABS operation for FDA. This draft emphasizes that:

"RABS can operate as 'doors closed' for processing with very low risk of contamination similar to isolators, or permit rare 'open door interventions' provided appropriate measures are taken (7)."

Opening the main doors during production is permissible and only requires in-depth documentation in exceptional cases. The same is not true for the transfer doors because the physical and aerodynamic barrier to the external area is only guaranteed when the doors are closed. Sometimes, industrial safety concerns prohibit the opening of RABS doors during production, regardless of aseptic considerations.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here